Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Stock Information for Passage Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Passage Bio Inc.

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.